Effects of 3 g of soluble fiber from oats on lipid levels of Asian Indians - a randomized controlled, parallel arm study

Seema Gulati, Anoop Misra, Ravindra M Pandey, Seema Gulati, Anoop Misra, Ravindra M Pandey

Abstract

Background: Cardiovascular diseases are more prevalent and severe in Asian Indians. Simple diet-based strategies are important for prevention of cardiovascular diseases.The aim of the present study was to evaluate the effects of oats consumption on lipid parameters in mildly hypercholesterolemic Asian Indians living in India.

Methods: A short-term, prospective, open-labeled, randomized controlled, parallel group study was conducted. Mildly hypercholesterolemic (total cholesterol >200 mg/dL and <240 mg/dL) subjects (n = 80) were randomized into two groups: intervention (n = 40) and usual diet (n = 40). Sample size was calculated for a two-group parallel superiority randomized control trial. Out of 80 enrolled subjects 69 subjects completed the study; 33 in the control group and 36 in the intervention group. In the intervention group, patients were served 70 g of oats twice a day in the form of porridge and upma (A thick porridge from oats with seasonings and vegetables) under observation at the study site. Lipid parameters were assessed at baseline and after 4 weeks of intervention.

Results: There was a reduction of 3.1% in total cholesterol levels in the control group as against 8.1% reduction in the intervention group (p < 0.02). Greater reductions were also seen in low-density lipoprotein cholesterol in the intervention group (11.6%) as compared to control group (4.1%, p < 0.04) over a period of 28 days.

Conclusion: Daily consumption of 3 g of soluble fiber from 70 g of oats leads to beneficial effects on the lipid parameters, specifically total cholesterol and low-density lipoprotein cholesterol in hypercholesterolemic Asian Indians. Large scale studies over a longer period of intervention are required to further establish the cholesterol-lowering effect of oat fiber.

Trial registration: The study was retrospectively registered at clinicaltrials.gov (dated: 25th Februrary.2015) with registration number NCT02376660 .

Figures

Fig. 1
Fig. 1
Study design

References

    1. Davis CE, Rifkind BM, Brenner H, et al. A single cholesterol measurement underestimates the risk of coronary heart disease. An empirical example from the lipid research clinics mortality follow-up study. JAMA. 1990;264(23):3044–3046. doi: 10.1001/jama.1990.03450230080033.
    1. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308(6925):367–372. doi: 10.1136/bmj.308.6925.367.
    1. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364(9438):937–952. doi: 10.1016/S0140-6736(04)17018-9.
    1. Padmavati S, Gupta S, Pantulu G, et al. Epidemiologic studies in Faridabad. Indian Heart J. 1961;13:275.
    1. Chadha S, Gopinath N, Shekhawat S. Urban–rural differences in the prevalence of coronary heart disease and its risk factors in Delhi. Bull World Health Organ. 1997;75(1):31.
    1. Joshi SR, Anjana RM, Deepa M, et al. Prevalence of dyslipidemia in urban and rural India: the ICMR–INDIAB study. PLoS One. 2014;9(5) doi: 10.1371/journal.pone.0096808.
    1. Chandra KS, Bansal M, Nair T, et al. Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart J. 2014;66(Suppl 3):S1–51. doi: 10.1016/j.ihj.2014.12.001.
    1. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S9–30. doi: 10.1210/jc.2008-1595.
    1. Misra A, Shrivastava U. Obesity and dyslipidemia in south Asians. Nutrients. 2013;5(7):2708–2733. doi: 10.3390/nu5072708.
    1. Othman RA, Moghadasian MH, Jones PJ. Cholesterol-lowering effects of oat beta-glucan. Nutr Rev. 2011;69(6):299–309. doi: 10.1111/j.1753-4887.2011.00401.x.
    1. Thies F, Masson LF, Boffetta P, et al. Oats and CVD risk markers: a systematic literature review. Br J Nutr. 2014;112(Suppl 2):S19–S30. doi: 10.1017/S0007114514002281.
    1. Kemppainen TA, Heikkinen MT, Ristikankare MK, et al. Nutrient intakes during diets including unkilned and large amounts of oats in celiac disease. Eur J Clin Nutr. 2010;64(1):62–67. doi: 10.1038/ejcn.2009.113.
    1. US Food and Drug Administration (FDA) Health claims: soluble fiber from certain foods and the risk of coronary heart disease (CHD) Code of Federal Regulations Title 21; Section 10181 [Internet] Silver Spring (MD): FDA 1997 [updated 2016 April 1; Available from: (Accessed on 27 March 2017)
    1. Bureau of Nutritional Sciences, Food Directorate, Health Products and Food Branch, Health Canada . Oat products and blood cholesterol lowering: summary of assessment of a health claim about oat products and blood cholesterol lowering [internet] Ottawa, Ontario: Health Canada; 2010.
    1. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA).Scientific opinion on the substantiation of a health claim related to oat beta-glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006.EFSA J 2010;8:1885–1900.
    1. Gulati S, Misra A, Pandey RM, et al. Effects of pistachio nuts on body composition, metabolic, inflammatory and oxidative stress parameters in Asian Indians with metabolic syndrome: a 24-wk, randomized control trial. Nutrition. 2014;30(2):192–197. doi: 10.1016/j.nut.2013.08.005.
    1. Nigam P, Bhatt S, Misra A, et al. Effect of a 6-month intervention with cooking oils containing a high concentration of monounsaturated fatty acids (olive and canola oils) compared with control oil in male Asian Indians with nonalcoholic fatty liver disease. Diabetes Technol Ther. 2014;16(4):255–261. doi: 10.1089/dia.2013.0178.
    1. O'Meara JG, Kardia SL, Armon JJ, et al. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med. 2004;164(12):1313–1318. doi: 10.1001/archinte.164.12.1313.
    1. Simon JA, Lin F, Hulley SB, et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the cholesterol and Pharmacogenetics (CAP) study. Am J Cardiol. 2006;97(6):843–850. doi: 10.1016/j.amjcard.2005.09.134.
    1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572. doi: 10.1001/jama.289.19.2560.
    1. Misra A, Alappan NK, Vikram NK, et al. Effect of supervised progressive resistance-exercise training protocol on insulin sensitivity, glycemia, lipids, and body composition in Asian Indians with type 2 diabetes. Diabetes Care. 2008;31(7):1282–7. doi: 10.2337/dc07-2316.
    1. Brown L, Rosner B, Willett WW, et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69(1):30–42.
    1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
    1. Drzikova B, Dongowski G, Gebhardt E. Dietary fibre-rich oat-based products affect serum lipids, microbiota, formation of short-chain fatty acids and steroids in rats. Br J Nutr. 2005;94(6):1012–1025. doi: 10.1079/BJN20051577.
    1. Andersson KE, Axling U, Xu J, et al. Diverse effects of oats on cholesterol metabolism in C57BL/6 mice correlate with expression of hepatic bile acid-producing enzymes. Eur J Nutr. 2013;52(7):1755–1769. doi: 10.1007/s00394-012-0479-1.
    1. Wolever TM, Gibbs AL, Brand-Miller J, et al. Bioactive oat beta-glucan reduces LDL cholesterol in Caucasians and non-Caucasians. Nutr J. 2011;10:130. doi: 10.1186/1475-2891-10-130.
    1. Hou Q, Li Y, Li L, Cheng G, Sun X, Li S, et al. The metabolic effects of oats intake in patients with type 2 diabetes: a systematic review and meta-analysis. Nutrients. 2015;7(12):10369–10387. doi: 10.3390/nu7125536.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi